
|Articles|November 15, 2003
FDA to allow inserts for keratoconus patients
Des Plaines, IL-Micro-thin prescription inserts (Intacs, Addition Technology Inc.) may be used to reduce or eliminate myopia and astigmatism in patients with keratoconus for whom restoration of functional vision is no longer possible with contact lenses or glasses, under a new designation by the FDA.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies
3
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
4
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis
5



























